Bellerophon Therapeutics (BLPH) Competitors $0.04 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsSustainabilityTrends BLPH vs. OGEN, KRBP, BON, PKBO, TRVN, CWBR, EVFM, REVB, PXMD, and PBLAShould you be buying Bellerophon Therapeutics stock or one of its competitors? The main competitors of Bellerophon Therapeutics include Oragenics (OGEN), Kiromic BioPharma (KRBP), Bon Natural Life (BON), Peak Bio (PKBO), Trevena (TRVN), CohBar (CWBR), Evofem Biosciences (EVFM), Revelation Biosciences (REVB), PaxMedica (PXMD), and Panbela Therapeutics (PBLA). These companies are all part of the "pharmaceutical products" industry. Bellerophon Therapeutics vs. Oragenics Kiromic BioPharma Bon Natural Life Peak Bio Trevena CohBar Evofem Biosciences Revelation Biosciences PaxMedica Panbela Therapeutics Bellerophon Therapeutics (NASDAQ:BLPH) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Do analysts recommend BLPH or OGEN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bellerophon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AOragenics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is BLPH or OGEN more profitable? Bellerophon Therapeutics' return on equity of 0.00% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets Bellerophon TherapeuticsN/A N/A N/A Oragenics N/A -1,077.64%-408.52% Does the media favor BLPH or OGEN? In the previous week, Bellerophon Therapeutics and Bellerophon Therapeutics both had 1 articles in the media. Bellerophon Therapeutics' average media sentiment score of 0.00 equaled Oragenics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bellerophon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oragenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, BLPH or OGEN? Bellerophon Therapeutics has higher earnings, but lower revenue than Oragenics. Bellerophon Therapeutics is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBellerophon TherapeuticsN/AN/A-$19.83M-$0.84-0.04Oragenics$40K43.80-$20.66M-$7.54-0.04 Do insiders and institutionals hold more shares of BLPH or OGEN? 10.6% of Bellerophon Therapeutics shares are held by institutional investors. Comparatively, 18.7% of Oragenics shares are held by institutional investors. 5.2% of Bellerophon Therapeutics shares are held by insiders. Comparatively, 24.6% of Oragenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, BLPH or OGEN? Bellerophon Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Does the MarketBeat Community favor BLPH or OGEN? Bellerophon Therapeutics received 319 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 58.00% of users gave Bellerophon Therapeutics an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformBellerophon TherapeuticsOutperform Votes31958.00% Underperform Votes23142.00% OragenicsOutperform VotesNo VotesUnderperform Votes31100.00% SummaryBellerophon Therapeutics beats Oragenics on 7 of the 11 factors compared between the two stocks. Ad Porter & CompanyRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Get Bellerophon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLPH vs. The Competition Export to ExcelMetricBellerophon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$440,000.00$6.75B$5.04B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio-0.0412.17130.2316.67Price / SalesN/A270.431,720.2276.26Price / CashN/A46.0936.9133.54Price / Book0.135.284.604.98Net Income-$19.83M$151.33M$114.94M$224.26M7 Day PerformanceN/A0.30%0.14%1.65%1 Month PerformanceN/A14.88%10.15%6.92%1 Year PerformanceN/A36.87%33.87%26.46% Bellerophon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLPHBellerophon Therapeutics0.3633 of 5 stars$0.04flatN/A-7.7%$440,000.00N/A-0.0420OGENOragenicsN/A$0.31+6.8%N/AN/A$1.75M$40,000.00-0.045Analyst ForecastKRBPKiromic BioPharmaN/A$1.12flatN/A+273.3%$1.73MN/A-0.1535BONBon Natural LifeN/A$1.38+1.5%N/A-70.2%$1.62M$25.56M0.00100Gap UpPKBOPeak BioN/A$0.07flatN/AN/A$1.62M$370,000.00-0.333TRVNTrevena1.34 of 5 stars$1.69-3.4%$125.00+7,296.4%-87.7%$1.45M$3.12M-0.0340Analyst ForecastGap UpCWBRCohBarN/A$0.49flatN/A-41.5%$1.42MN/A0.0010EVFMEvofem Biosciences0.7724 of 5 stars$0.01flatN/A-80.6%$1.42M$11.39M-0.03120Gap DownREVBRevelation Biosciences0.8675 of 5 stars$0.85+3.7%N/A-95.4%$1.39MN/A-0.0310PXMDPaxMedica1.3208 of 5 stars$0.12flat$3.00+2,442.4%-95.5%$1.34MN/A0.002PBLAPanbela Therapeutics0.9639 of 5 stars$0.37flat$500.00+135,035.1%-97.4%$1.29MN/A0.007 Related Companies and Tools Related Companies Oragenics Alternatives Kiromic BioPharma Alternatives Bon Natural Life Alternatives Peak Bio Alternatives Trevena Alternatives CohBar Alternatives Evofem Biosciences Alternatives Revelation Biosciences Alternatives PaxMedica Alternatives Panbela Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLPH) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
